Juanita Valdes Camacho, MD
Pediatric Medicine · Shreveport
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Lsu Health Sciences Center Shreveport Faculty Group Practice · 567 clinicians in this group
Hospitals listed: Ochsner Lsu Health Shreveport · Ochsner Lsu Health Shreveport-St Mary Medical Cent. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Camacho’s office at (318) 675-5000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A162224 · Delinquent
Licence status: Delinquent · since 2019 · expires 2023-04-30 · Greater College of Our Lady of the Rosary.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Ochsner Lsu Health ShreveportShreveport, LAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Ochsner Health System, which runs 36 hospitals in 3 statesPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.124, Oct 2024 – Sep 2025
- Ochsner Lsu Health Shreveport-St Mary Medical CentShreveport, LAAcute Care Hospital · Voluntary non-profit - Private · No emergency department · Birthing-friendlyPart of Ochsner Health System, which runs 36 hospitals in 3 statesPatients rate it 4 of 5 · 75% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Ochsner Lsu Health Shreveport
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 3 better, 3 the same, 0 worse of 6 measures. Readmissions: 1 better, 7 the same, 0 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.124 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.91 (0 to 1.92) · 594 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.11 (0.78 to 1.45) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 164.33 (120.57 to 208.1) · 91 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.3 · 67 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.2 · 57 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.1 · 420 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.2 · 1,578 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.41 (0.19 to 0.63) · 3,331 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.43) · 3,282 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.09 (2.02 to 6.17) · 1,096 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.85 (0.24 to 3.47) · 559 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.72 (1.3 to 4.15) · 1,132 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 12.21 (4.96 to 19.47) · 488 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.19 (1.49 to 8.9) · 500 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.64 (0.16 to 3.11) · 162 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.59 (0 to 1.29) · 3,025 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.665 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.912 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.444 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 2.022 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.6 · 60 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.4 · 190 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -54.5 · 81 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -16 · 61 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 105 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.6 (3.8 to 8.1) · 122 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.9 (7.2 to 13.3) · 122 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 112 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.6 to 17.3) · 450 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.4) · 222 cases | No different | Jan 2024 – Dec 2024 |
What patients said (548 patients answered, 15% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 4 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 69% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Ochsner Lsu Health Shreveport-St Mary Medical Cent
Behind the star rating — Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 0 better, 3 the same, 0 worse of 3 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.48 to 1.51) | No different | Jul 2022 – Jun 2024 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 30 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.45) · 42 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.05 to 0.49) · 40 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.5 (0.85 to 6.14) · 30 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.67 (0 to 3.41) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.6 to 4.07) · 30 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.29 (0 to 19.43) · 30 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.23 (0.89 to 9.58) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.722 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.932 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.2 to 8.1) · 125 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.3 (6 to 14) · 125 cases | No different | Jan 2024 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 537 cases | No different | Jan 2024 – Dec 2024 |
What patients said (279 patients answered, 11% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 81% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 80% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 68% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 53% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$7,582
Medicare paid this office $7,582 for 42 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 17 | $1,782 | $69 |
| Return visit (30+ min) | 14 | $1,596 | $73 |
Who their Medicare patients are
42 Original Medicare patients in 2024. Average age 70 · Women 74% · Also on Medicaid 36% · Health risk score 1.29. At or below the middle of the specialty; the typical pediatric medicine clinician is at 1.4.
Conditions among them: High blood pressure 75% · Depression 33% · Diabetes 31% · COPD 31%.
The office billed $22,630, Medicare allowed $9,875 and paid $7,582; for 388 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 42 | 388 | 70 | 1.29 | $22,630 | $7,582 |
| 2023 | 45 | 304 | 67 | 1.46 | $21,073 | $7,359 |
| 2022 | 66 | 622 | 63 | 1.29 | $30,897 | $10,827 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Return visit (30+ min) | 23 | $2,305 | $74 |
2022: 2 services
| Return visit (30+ min) | 37 | $3,335 | $71 |
| New patient visit (45+ min) | 14 | $1,487 | $106 |
Medicaid work
$532,676 in 2024
Medicaid paid $532,676 for 7,927 billed services this clinician did in 2024, up to 110 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Percutaneous tests (scratch, puncture, prick) with allergenic extracts, immediate type reaction, including test interpretation and report, specify number of tests | 530 | $249,963 |
| Return visit (30+ min) | 1,553 | $136,320 |
| New patient visit (45+ min) | 372 | $49,596 |
| Short return visit (20+ min) | 757 | $24,830 |
| New patient visit (60+ min) | 124 | $20,122 |
| Long return visit (40+ min) | 276 | $11,751 |
| ALLERGEN SPEC IGE CRUDE ALLERGEN EXTRACT EACH | 247 | $10,422 |
| Respiratory flow volume loop | 199 | $9,915 |
| ANTIGEN THERAPY SERVICES | 19 | $6,942 |
| OFF/OP EST MAY X REQ PHY/QHP | 201 | $5,656 |
| Nitric oxide expired gas determination | 46 | $2,500 |
| EVALUATION OF WHEEZING | 42 | $1,568 |
| 2024 | 7,927 | 27 | 110 | $532,676 |
| 2023 | 9,063 | 28 | 102 | $621,978 |
| 2022 | 5,137 | 21 | 133 | $428,486 |
See the largest Medicaid services in earlier years
2023
| Percutaneous tests (scratch, puncture, prick) with allergenic extracts, immediate type reaction, including test interpretation and report, specify number of tests | 606 | $286,568 |
| Return visit (30+ min) | 1,691 | $135,334 |
| New patient visit (45+ min) | 520 | $65,556 |
| Long return visit (40+ min) | 625 | $53,943 |
| New patient visit (60+ min) | 124 | $21,447 |
| Short return visit (20+ min) | 525 | $17,834 |
| Respiratory flow volume loop | 386 | $16,654 |
| ALLERGEN SPEC IGE CRUDE ALLERGEN EXTRACT EACH | 312 | $12,705 |
| Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device | 239 | $4,434 |
| OFF/OP EST MAY X REQ PHY/QHP | 154 | $3,883 |
| Professional services for allergen immunotherapy not including provision of allergenic extracts; 2 or more injections | 87 | $1,216 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 251 | $591 |
2022
| Percutaneous tests (scratch, puncture, prick) with allergenic extracts, immediate type reaction, including test interpretation and report, specify number of tests | 490 | $211,526 |
| Return visit (30+ min) | 1,172 | $99,708 |
| New patient visit (45+ min) | 404 | $51,878 |
| Long return visit (40+ min) | 317 | $32,624 |
| Short return visit (20+ min) | 408 | $13,678 |
| New patient visit (60+ min) | 46 | $7,105 |
| Respiratory flow volume loop | 89 | $5,878 |
| New patient visit (30+ min) | 32 | $3,097 |
| EVALUATION OF WHEEZING | 12 | $2,040 |
| Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device | 254 | $590 |
| Nitric oxide expired gas determination | 14 | $363 |
| Medication list documented in medical record (COA) | 641 | $0 |
Drugs they prescribed that Part D paid
$259,330
Pharmacies billed $259,330 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 291) in 2024. At or below the middle of the specialty; the typical pediatric medicine clinician is at 0%.
182 generic and 109 brand-name prescriptions · $259,330 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 36 | $143,423 | $3,984 |
| Dupixent | 20 | $82,492 | $4,125 |
| Fluticasone Propionate | 62 | $1,053 | $17 |
| Azelastine | 25 | $747 | $30 |
| Ipratropium | 23 | $340 | $15 |
See all 7 drugs
| Dupixent | 36 | $143,423 | $3,984 |
| Dupixent | 20 | $82,492 | $4,125 |
| Fluticasone Propionate | 62 | $1,053 | $17 |
| Azelastine | 25 | $747 | $30 |
| Ipratropium | 23 | $340 | $15 |
| Triamcinolone Acetonide | 13 | $185 | $14 |
| Gabapentin | 13 | $100 | $8 |
Year by year
| 2024 | 291 | 65 | 0% (0) | 37% | $259,330 |
| 2023 | 185 | 46 | 0% (0) | 32% | $113,548 |
| 2022 | 44 | 19 | 0% (0) | 43% | $35,934 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Azelastine | 16 | $432 | $27 |
| Albuterol Sulfate Hfa | 11 | $405 | $37 |
| Fluticasone Propionate | 18 | $262 | $15 |
| Ipratropium | 23 | $190 | $8 |
| Triamcinolone Acetonide | 13 | $136 | $10 |
Money from drug and device companies
$3,043 in 2025
| 2025 | 20 | 107 | None | $3,043 |
| 2024 | 13 | 64 | None | $1,969 |
| 2023 | 15 | 74 | None | $1,720 |
| 2022 | 12 | 53 | None | $1,360 |
| 2021 | 2 | 2 | None | $29 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Fasenra | $520 | 14 payments
|
| Pharming Healthcare | Ruconest | $332 | 7 payments
|
| BioCryst US Sales Co. | Orladeyo | $290 | 5 payments
|
| GlaxoSmithKline | Nucala | $285 | 12 payments
|
| Amgen | Actimmune | $275 | 9 payments
|
| Regeneron Healthcare Solutions | Dupixent | $261 | 12 payments
|
See all 98 published payments
| Novartis Pharmaceuticals | Meals · 2025-12-11 | Rhapsido | $19 |
| GlaxoSmithKline | Meals · 2025-12-10 | Nucala | $24 |
| BioCryst US Sales Co. | Meals · 2025-12-08 | None | $138 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-04 | Tezspire | $23 |
| Regeneron Healthcare Solutions | Meals · 2025-12-02 | Dupixent | $18 |
| ARS Pharmaceuticals Operations | Meals · 2025-12-01 | Neffy | $6 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-20 | Fasenra | $21 |
| Pharming Healthcare | Meals · 2025-11-18 | Ruconest | $22 |
| GlaxoSmithKline | Meals · 2025-11-13 | Nucala | $21 |
| Ionis Pharmaceuticals | Meals · 2025-11-13 | Dawnzera | $125 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-11 | None | $20 |
| GlaxoSmithKline | Meals · 2025-11-10 | Nucala | $17 |
| Pharming Healthcare | Meals · 2025-11-08 | Ruconest | $72 |
| BioCryst US Sales Co. | Meals · 2025-10-31 | None | $16 |
| Novartis Pharmaceuticals | Meals · 2025-10-30 | Rhapsido | $17 |
| CSL Behring | Meals · 2025-10-24 | Hizentra | $37 |
| Genzyme | Meals · 2025-10-21 | Dupixent | $18 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-17 | Fasenra | $20 |
| BioCryst US Sales Co. | Meals · 2025-10-16 | Orladeyo | $30 |
| Novartis Pharmaceuticals | Meals · 2025-10-15 | Rhapsido | $29 |
| Amgen | Meals · 2025-10-09 | Tezspire | $13 |
| GlaxoSmithKline | Meals · 2025-10-08 | Nucala | $28 |
| Regeneron Healthcare Solutions | Meals · 2025-10-07 | Dupixent | $27 |
| Novartis Pharmaceuticals | Meals · 2025-10-06 | Rhapsido | $7 |
| Novartis Pharmaceuticals | Meals · 2025-10-06 | Rhapsido | $13 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-02 | Tezspire | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-02 | Tezspire | $125 |
| Grifols USA | Meals · 2025-09-30 | Xembify | $35 |
| Regeneron Healthcare Solutions | Meals · 2025-09-23 | Dupixent | $22 |
| Greer Laboratories | Meals · 2025-09-23 | Palforzia | $16 |
| ARS Pharmaceuticals Operations | Meals · 2025-09-19 | Neffy | $8 |
| Novartis Pharmaceuticals | Meals · 2025-09-18 | None | $22 |
| Genzyme | Meals · 2025-09-16 | Dupixent | $19 |
| Pharming Healthcare | Meals · 2025-09-09 | Ruconest | $28 |
| GlaxoSmithKline | Meals · 2025-09-08 | Nucala | $28 |
| Amgen | Meals · 2025-09-04 | Tezspire | $18 |
| Hospira | Meals · 2025-08-25 | Octagam Immune Globulin (Human) | $14 |
| Novartis Pharmaceuticals | Meals · 2025-08-19 | None | $22 |
| Genzyme | Meals · 2025-08-18 | Dupixent | $18 |
| ARS Pharmaceuticals Operations | Meals · 2025-08-16 | Neffy | $8 |
| Genentech USA | Meals · 2025-08-14 | Xolair | $20 |
| Galderma Laboratories L.P. | Meals · 2025-08-07 | Nemluvio | $19 |
| Amgen | Meals · 2025-08-05 | Tezspire | $13 |
| GlaxoSmithKline | Meals · 2025-08-04 | Nucala | $28 |
| Boston Scientific | Meals · 2025-07-26 | Accolade Sr | $34 |
| Lilly USA | Meals · 2025-07-25 | Ebglyss | $15 |
| Pharming Healthcare | Meals · 2025-07-23 | Ruconest | $81 |
| Genentech USA | Meals · 2025-07-23 | Xolair | $19 |
| Novartis Pharmaceuticals | Meals · 2025-07-21 | None | $23 |
| Regeneron Healthcare Solutions | Meals · 2025-07-15 | Dupixent | $31 |
| GlaxoSmithKline | Meals · 2025-07-09 | Nucala | $22 |
| Pharming Healthcare | Meals · 2025-07-08 | Ruconest | $30 |
| Genzyme | Meals · 2025-07-02 | Dupixent | $18 |
| Novartis Pharmaceuticals | Meals · 2025-06-24 | None | $19 |
| Novartis Pharmaceuticals | Meals · 2025-06-24 | None | $5 |
| BioCryst US Sales Co. | Meals · 2025-06-21 | Orladeyo | $77 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-20 | Fasenra | $79 |
| Regeneron Healthcare Solutions | Meals · 2025-06-19 | Dupixent | $15 |
| GlaxoSmithKline | Meals · 2025-06-16 | Nucala | $22 |
| Verona Pharma | Meals · 2025-06-13 | Ohtuvayre | $25 |
| Amgen | Meals · 2025-06-05 | Tezspire | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-04 | Airsupra | $22 |
| Genzyme | Meals · 2025-05-29 | Dupixent | $18 |
| Lilly USA | Meals · 2025-05-27 | Ebglyss | $19 |
| Genentech USA | Meals · 2025-05-22 | Xolair | $18 |
| Amgen | Meals · 2025-05-22 | Actimmune | $148 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-21 | Fasenra | $16 |
| BioCryst US Sales Co. | Meals · 2025-05-16 | Orladeyo | $29 |
| ARS Pharmaceuticals Operations | Meals · 2025-05-15 | Neffy | $108 |
| GlaxoSmithKline | Meals · 2025-05-14 | Nucala | $23 |
| Verona Pharma | Meals · 2025-05-08 | Ohtuvayre | $14 |
| Regeneron Healthcare Solutions | Meals · 2025-05-06 | Dupixent | $22 |
| Pharming Healthcare | Meals · 2025-04-29 | Ruconest | $27 |
| Regeneron Healthcare Solutions | Meals · 2025-04-22 | Dupixent | $25 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-17 | Fasenra | $15 |
| Pharming Healthcare | Meals · 2025-04-09 | Ruconest | $74 |
| Regeneron Healthcare Solutions | Meals · 2025-04-09 | Dupixent | $13 |
| GlaxoSmithKline | Meals · 2025-04-07 | Nucala | $21 |
| Amgen | Meals · 2025-04-04 | Actimmune | $29 |
| Amgen | Meals · 2025-04-03 | Tezspire | $12 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-27 | None | $17 |
| Novartis Pharmaceuticals | Meals · 2025-03-20 | None | $19 |
| Regeneron Healthcare Solutions | Meals · 2025-03-04 | Dupixent | $15 |
| BioCryst Pharmaceuticals | Meals · 2025-03-03 | Orladeyo | $131 |
| Novartis Pharmaceuticals | Meals · 2025-03-02 | None | $44 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-02 | None | $78 |
| GlaxoSmithKline | Meals · 2025-02-14 | Nucala | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-12 | Fasenra | $15 |
| Regeneron Healthcare Solutions | Meals · 2025-02-11 | Dupixent | $31 |
| Regeneron Healthcare Solutions | Meals · 2025-02-05 | Dupixent | $17 |
| ARS Pharmaceuticals Operations | Meals · 2025-01-31 | Neffy | $19 |
| GlaxoSmithKline | Meals · 2025-01-29 | Nucala | $25 |
| Regeneron Healthcare Solutions | Meals · 2025-01-28 | Dupixent | $26 |
| Amgen | Meals · 2025-01-22 | Actimmune | $11 |
| Verona Pharma | Meals · 2025-01-22 | Ohtuvayre | $21 |
| Amgen | Meals · 2025-01-17 | Actimmune | $11 |
| CSL Behring | Meals · 2025-01-16 | Haegarda | $36 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-03 | Fasenra | $50 |
See earlier years (2024, 2023, 2022, 2021)
2024: $1,969
| BioCryst US Sales Co. | Orladeyo | $546 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $389 | 14 payments
|
| Regeneron Healthcare Solutions | Dupixent | $387 | 13 payments
|
| Amgen | Actimmune | $148 | 6 payments
|
| GlaxoSmithKline | Nucala | $111 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $89 | 3 payments
|
| Genzyme | Dupixent | $85 | 5 payments
|
| CSL Behring | Hizentra | $69 | 2 payments
|
| Blueprint Medicines | Ayvakit | $48 | 1 payment
|
| Genentech USA | Xolair | $34 | 2 payments
|
| Greer Laboratories | Palforzia | $23 | 1 payment
|
| Itamar Medical | Watchpatone | $22 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Glassia | $16 | 1 payment
|
2023: $1,720
| BioCryst US Sales Co. | Orladeyo | $465 | 11 payments
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $331 | 14 payments
|
| Regeneron Healthcare Solutions | Dupixent | $235 | 12 payments
|
| Horizon Therapeutics plc | Actimmune | $132 | 2 payments
|
| Genentech USA | Xolair | $113 | 7 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $92 | 4 payments
|
| Grifols USA | Xembify | $77 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Cuvitru | $49 | 2 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $47 | 2 payments
|
| Inogen | Inogen One G5 Oxygen Concentrator - Bluetooth | $43 | 4 payments
|
| Genzyme | Dupixent | $40 | 2 payments
|
| CSL Behring | Hizentra | $33 | 1 payment
|
| Aimmune Therapeutics | Palforzia | $29 | 1 payment
|
| Amgen | Tezspire | $19 | 1 payment
|
| Blueprint Medicines | Ayvakit | $14 | 1 payment
|
2022: $1,360
| AstraZeneca Pharmaceuticals LP | Tezspire | $378 | 15 payments
|
| Regeneron Healthcare Solutions | Dupixent | $228 | 8 payments
|
| CSL Behring | Haegarda | $167 | 4 payments
|
| Horizon Therapeutics plc | Actimmune | $108 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $92 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Takhzyro | $79 | 2 payments
|
| Aimmune Therapeutics | Palforzia | $71 | 3 payments
|
| Amgen | Tezspire | $53 | 3 payments
|
| GlaxoSmithKline | Nucala | $51 | 3 payments
|
| Genzyme | Dupixent | $50 | 2 payments
|
| BioCryst US Sales Co. | Orladeyo | $46 | 1 payment
|
| Merck Sharp & Dohme | None | $36 | 1 payment
|
2021: $29
| ALK-Abello | Odactra | $16 | 1 payment
|
| Horizon Therapeutics plc | Actimmune | $13 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Kedrion Biopharma, Inc. · Kedben60-0d1omg · 2024 | Their institution | $23,936 |
| Kedrion Biopharma, Inc. · Kedben60-0d1omg · 2025 | Their institution | $21,127 |
Professional record
- NPI
- 1902267222
- Licence
- CA A162224California A162224: Delinquent · expires 2023-04-30
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0201X (2080P0201X); Pediatrics (208000000X)
- Mailing address
- 1541 Kings Hwy, Attn: Payor Credentialing, Shreveport, LA, 71103
- NPI first listed
- 2016-03-14
- NPI last updated
- 2026-03-12
- NPI record certified
- 2026-03-12
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 730 Welch Rd, Palo Alto, CA, 94304 · 703 Main St, Paterson, NJ, 07503